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Purpose: Stereotactic radiosurgery (SRS) is the preferred primary treatment option for
patients with a limited number of asymptomatic brain metastases. In case of relapse
after initial SRS the optimal salvage treatment is not well defined. Within this retrospective
analysis, we investigated the feasibility of repeated courses of SRS to defer Whole-Brain
Radiation Therapy (WBRT) and aimed to derive prognostic factors for patient selection.
Materials and Methods: From 2014 until 2017, 42 patients with 197 brain metastases
have been treated with multiple courses of SRS at our institution. Treatment was delivered
as single fraction (18 or 20Gy) or hypo-fractionated (6 fractions with 5Gy) radiosurgery.
Regular follow-up included clinical examination and contrast-enhanced cMRI at 3–4
months’ intervals. Besides clinical and treatment related factors, brain metastasis velocity
(BMV) as a newly described clinical prognostic metric was included and calculated
between first and second treatment.
Results: A median number of 1 lesion (range: 1–13) per course and a median
of 2 courses (range: 2–6) per patient were administered resulting in a median
of 4 (range: 2–14) metastases treated over time per patient. The median interval
between SRS courses was 5.8 months (range: 0.9–35 months). With a median
follow-up of 17.4 months (range: 4.6–45.5 months) after the first course of treatment,
a local control rate of 84% was observed after 1 year and 67% after 2 years.
Median time to out-of-field-brain-failure (OOFBF) was 7 months (95%CI 4–8 months).
WBRT as a salvage treatment was eventually required in 7 patients (16.6%).
Median overall survival (OS) has not been reached. Grouped by ds-GPA (≤2 vs.
>2) the survival curves showed a significant split (p = 0.039). OS differed also
significantly between BMV-risk groups when grouped into low vs. intermediate/high
risk groups (p = 0.025). No grade 4 or 5 acute or late toxicity was observed.
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Conclusion: In selected patients with relapse after SRS for brain metastases, repeat
courses of SRS were safe and minimized the need for rescue WBRT. The innovative, yet
easy to calculate metric BMV may facilitate treatment decisions as a prognostic factor
for OS.
Keywords: brainmetastases (BM), stereotactic radiosurgery, repeat radiosurgery, brainmetastasis velocity, whole
brain radiation therapy (WBRT), salvage radiation therapy (SRT)
INTRODUCTION
Treatment of brain metastases is still a challenge since different
treatment goals need to be weighed: for one thing preventing
progression of metastases with its associated neurological
deterioration then again ensuring quality of life and limiting
treatment-associated morbidity (1). In the past, whole-brain
radiation therapy (WBRT) was standard of care for symptom
control and presumably prolonged survival. Still, with its risk of
neurotoxicity and early functional impairment (2–5), its inferior
rate of local control (6) and its questionable impact on overall
survival (7) the role ofWBRT in the treatment of limited numbers
of brain metastases (≤4) has been challenged and transformed
over the past 10 years.
Brain metastases serve as the ideal target for stereotactic
radiosurgery (SRS) (1, 8) and the efficacy of this treatment has
been proven in several prospective phase III trials (2, 4, 6, 9).
Consequently, SRS alone has been recommended within national
guidelines as the preferred radiation treatment option for up to
four asymptomatic brain metastases (1, 10, 11) to defer WBRT.
For patients with more than 4 metastases SRS withoutWBRT has
equally shown encouraging results regarding overall survival and
toxicity (12).
Despite the excellent local control rates of SRS only, up to
50% of patients will present with new brain metastases within a
year in terms of distant brain failure (4, 6, 9, 12). The optimal
salvage treatment in this situation has not yet been defined.
WBRT is still administered, but challenges to WBRT remain the
same as in the primary situation. Furthermore, the concept of
salvage WBRT has been investigated particularly as a subset of
patients with long term WBRT-free survival can be identified
by predictive parameters (13). Therefore, repeat radiosurgery for
new brain metastases to defer or even avoid WBRT represents
an attractive concept, although data considering efficacy, safety
or optimal patient selection is still missing. Only few groups
have recently reported retrospective analyses of their experience
with repeated courses of radiosurgery (14–18) and hence optimal
patient selection appears crucial.
The graded prognostic assessment (GPA) predicts survival
upon the initial diagnosis of brain metastases (19–22) and
potentially remains prognostic for new lesions treated with
repeated courses of SRS (23). Recently, Farris et al. have
introduced a novel metric, prognostic of overall survival: the
clinical metric brain metastasis velocity (BMV) serves as an
estimate for development of new metastases over time and is
not only associated with overall survival, but also predicts need
of salvage therapy in case of distant brain failure or risk of
neurological death (24).
Within this retrospective study, we present our results of
the feasibility, toxicity, and outcome of repeated courses of
radiosurgery for the treatment of new brain metastases and
examine the value of the metric BMV.
PATIENTS AND METHODS
Patient Eligibility
From February 2014 until August 2017, 42 patients with 197
brain metastases were treated with at least 2 courses of SRS for
either intact brain lesions or resection cavities at the University
Hospital of Zurich. According to institutional standards, repeat
SRS was given, if all new lesions (≤9 lesions at a time) were
deemed amenable for SRS (criteria defined in treatment section)
and the patient was assessed in good performance status by the
treating physician. A multi-disciplinary tumor board approved
all indications.
All patients received a physical examination and an
oncological re-staging by either computed tomography (CT)
imaging or combined whole body positron emission tomography
(PET) with CT imaging. Cerebral metastases were assessed by
contrast enhanced high-resolution cranial magnetic resonance
imaging (MRI).
Treatment
According to institutional guidelines following international
recommendations (1, 9, 12, 25, 26) treatment was delivered as
follows:
All patients were immobilized using a dedicated frame-less
stereotactic mask system (CIVCO Medical Solutions, Coralville,
IA, USA). Planning-CT was done in treatment position using a
0.75–1mm slice thickness and intravenous (IV) contrast agent.
A dedicated planning MRI with IV contrast agent including
a volumetric T1 sequence and a slice thickness of 0.6mm
was acquired. Both image modalities were fused using rigid
image registration for target delineation. For contouring, the
MRI-visible gross tumor volume (GTV) was delineated without
additional margin as clinical target volume (CTV). The planning
target volume (PTV) was derived by adding an isotropic margin
of 1mm. In contrast, for resected brain metastases the cavities
were delineated as CTV. In this case, the PTV was derived
by adding an isotropic margin of 2mm. Patients were grouped
for dose prescription: For 1–4 small metastases with diameter
of ≤2.5 cm each, a single fraction scheme was used (1 × 18–
20Gy). If metastases measured> 2.5 cm, 6 fractions of 5Gy were
prescribed. For patients with 5–9 metastases, the threshold was
a diameter of 1 cm for either single doses SRS or, if larger in
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size, 6 fractions of 5Gy was used. If >9 metastases were treated,
the regimen with 6 fractions was also favored. Postsurgical
treatments were delivered in 6 × 5Gy. All doses were prescribed
to the PTV encompassing the 80%-isodose line and delivered as
Volumetric Modulated Arc Therapy (VMAT) using True Beam
or Edge linear accelerators (LINACs) (Varian Medical Systems,
Inc., Palo Alto, CA, USA).
Toxicity and Endpoint Definitions
We followed patients from time of initial SRS until death or
closure of data-entry. For the first year, cMRI and clinical
examination were appointed every 3 months and thereafter at
4 months’ intervals. Toxicity was graded according to National
Cancer Institute Common Terminology Criteria for Adverse
Events (CTCAE v4.0) and classified as acute (up to 3months after
respective course of SRS) or late toxicity.
Treatment response and radiation necrosis (RN) as an
adverse event were investigated following recommendations of
the response assessment in neuro- oncology (RANO)-group
(27). Gadolinium-enhanced MRI served as a basis for response
assessment. Local control (LC) of a treated lesion was defined
as either response or stable disease in the last follow-up cMRI
scans. Newly diagnosed out-of-field lesions were regarded as
TABLE 1 | Baseline patient characteristics.
Characteristics n (%)
Total 42
GENDER
Male 20 (48)
Female 22 (52)
AGE (Y)*
Median (range) 59 (35–84)
HISTOLOGY
Non-small cell lung carcinoma 20 (48)
Melanoma 7 (17)
Breast 6 (14)
Other 9 (21)
KPS (%)*
<70 1 (2)
70–80 16 (38)
90–100 25 (60)
Ds-GPA*
Median (range) 2 (1–4)
PATIENTS PER COURSE
Course no. 1 42 (100)
Course no. 2 42 (100)
Course no. 3 10 (24)
Course no. 4 3 (7)
Course no. 5 2 (5)
Course no. 6 1 (2)
*At time of first treatment. Values are numbers (percentage) except where noted
otherwise.
Ds-GPA, Diagnostic-specific graded prognostic assessment score; KPS, Karnofsky
performance status.
out of field brain failure (OOFBF). In order to distinguish
between true progression and pseudo-progression, time course
over all follow-up MRI-scans was taken in account (28). The
diagnosis of RN followed the RANO and was derived by
suggested multimodal diagnostics (29): if RN was suspected
in standard cMRI, susceptibility-weighted contrast enhanced
(DSC) perfusion MRI or 18F-Fluorethyltyrosin (18FLT)-PET
were performed. A RN was called symptomatic RN if a patient
presented with clinical symptoms as nausea, headache or fatigue.
Dying with increased or new neurological dysfunction
or progressive metastases was considered neurological death,
whereas the status of stable metastases was not (30).
Statistics
Actuarial survival time and tumor control as freedom from local
failure (LF) or OOFBF were calculated according to the Kaplan-
Meier method. OOFBF was assessed patient-specifically after the
individual courses. In contrast, freedom from LF was determined
as lesion-specific local control from time of corresponding course
to date of the event. Overall survival was calculated from each
course of SRS to the time of death.
To analyze prognostic factors for OS a Cox proportional
hazard model (P < 0.05) was trained. Primarily a univariate
analysis was performed, followed by a multivariate analysis
of factors that were prognostic on univariate level. Histology
(NSCLC vs. others) and diagnostic-specific GPA (0–2 vs. 2.5–4)
were analyzed as categorical variables.
BMV was calculated as the cumulative number of new brain
metastases that developed since initial SRS over time. Within our
TABLE 2 | Lesion and treatment characteristics.
Characteristics n (%)
Total lesions 197
SRS target* 121 (61)
FSRT target 76 (39)
Intact metastasis 49 (25)
Post-resection cavity 27 (14)
VOLUME GTV (cm3)
Median (range) 0.3 (0.1–39.4)
Median volume SRS lesions (range) 0.1 (0.1–8.2)
Median volume FSRT lesions (range) 2.45 (0.1–39.4)
VOLUME PTV (cm3)
Median PTV overall (range) 0.7 (0.1–55.4)
AGGREGATED VOLUME (AV) PER COURSE p.P. (cm3)
Median AV p.P. over all courses 1.2 (0.1–48.4)
DOSE PRESCRIPTION
1 × 18Gy 15 (8)
1 × 20Gy 106 (54)
6 × 5Gy 76 (38)
SRS/FSRT prescription isodose line 80%
Values are numbers (percentage) except where noted otherwise.
SRS, Stereotactic radiosurgery; FSRT, fractionated stereotactic radiotherapy; p.P, per
patient.
*With SRS, only intact metastasis and no post-resection cavities were treated.
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cohort it was determined at time of first DBF after the first course
of SRS treatment. According to proposed risk profile groups (24),
patients were classified as follows:
• low risk: <4 new metastases/year.
• intermediate risk: 4–13 new metastases/year.
• high risk: >13 new metastases/year.
RESULTS
Patient, Tumor, and Treatment
Characteristics
We identified 42 consecutive patients who received repeated
courses of SRS from our institutional database at the University-
Hospital Zurich. At time of first treatment most presented with
good Karnofsky performance status (KPS) of median of 80%
(range: 50–100%) and a median age of 56 years (range: 35–83
years). Ds-GPA was calculated individually with a median of
2.5 (range: 1–4). 12 of 23 patients (52%) presented with non-
small cellular lung carcinoma as primary tumor diagnosis; 9 of
these with adenocarcinoma. Further patient characteristics are
summarized in Table 1.
Within the observation period, a total number of 197
metastases from 100 SRS courses was treated. The median size of
the GTV was 0.3 cm3 (range: 0.1–39.4 cm3) whereas the median
size of the PTV was 0.7 cm3 (range: 0.1–55.4 cm3). The sum of
all GTVs for a single patient at one treatment period was defined
as aggregated volume (AV). The median AV per course was 1.2
cm3 (range: 0.1–48.4 cm3). Hundred and Twenty-One (61%) of
the lesions were treated with a single dose SRS of 18 or 20Gy.
The remaining 76 lesions received fractionated treatments of 6
fractions with 5Gy single dose (see treatment characteristics in
Table 2).
Ds-GPA Score
As Figure 1 demonstrates the median ds-GPA remained stable
during the entire treatment time. However, a shift of the quartiles
FIGURE 1 | Course specific GPA. Boxplot showing median, 1st and 3rd
quartile and 95% CI. A median GPA of 2 for all courses was observed.
and the range toward lower ds-GPA values was obvious within
subsequent treatment courses.
Brain Metastasis Velocity
Median 3.5 newmetastases / year (range: 0.3–22.1) were observed
at time of first distant failure. Twenty-Three of Forty-Two
patients (55%) could be grouped within low-risk (<4 new
metastases/year), Twelve (28%) had an intermediate-risk (4–13
new metastases/year), and Seven of Forty-patients (17%) were in
the high-risk group (>13 new metastases/year).
Brain Tumor Control
With a median follow-up of 17.4 months (range: 4.6–45.5
months) after the first course of treatment a local control rate of
84% was observed at 1 year and 67% at 2 years independently
of treatment course. Figure 2 shows Kaplan-Meier-Plot for local
control. There was no statistically significant difference to be
found between lesions treated with SRS vs. fSRT (p= 0.6).
Considering overall brain control, median time to out-of-
field-brain-failure (OOFBF) was 7 months (95%CI 4–8 months)
after the first treatment and 6 months (95%CI 3–17 months)
after the second. One-year and Two-year cumulative incidence of
OOFBF after first course was 83 and 95%, respectively. Figure 3
shows Kaplan-Meier-Plot for OOFBF.
Salvage WBRT
Seven of Forty-Two (16.6%) patients were not amenable to
another course of repeat SRS at time of second recurrence and
had receivedWBRT within a median interval of 6 months (range:
4–13 months) to the first SRS course.
FIGURE 2 | Kaplan-Meier-Plot for local control. For 189 lesions (with at least
one follow-up with cMRI) a 1-year local control rate of 84% was observed,
calculated from time of corresponding course to date of the event. Censored
in case no event occurred or if WBRT had to be administered.
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FIGURE 3 | Kaplan-Meier-Plot for out-of-field brain control after 1st treatment
course. Censored in case no event occurred or if WBRT had to be
administered.
Patient Survival: Univariate and
Multivariate Analysis
From date of first diagnosis of brain metastases a median OS
has not been reached at time of final analysis. As Figure 4
demonstrates, the survival curves showed a significant split
(p = 0.039), when grouped by ds-GPA (≤2 vs. >2). The median
OS for patients with a ds-GPA >2 after diagnosis of first brain
metastasis has not been achieved. A median OS of 21 months
(95% CI: 17-NA) for patients with ds-GPA ≤2 was observed.
BMV proved to be a prognostic metric for OS calculated
from time of first distant-brain-failure. Figure 5 displays how
survival curves differ significantly for low-risk (23 patients,
55%) vs. intermediate- and high-risk patients (19 patients, 45%)
(p = 0.025). Median OS from time of first DBF for the low-
risk group has not been reached, whereas the median OS for the
combined group was 10 months (95% CI: 7-NA).
At time of last follow-up 28 of 42 (67%) patients were
still alive. Eight of Fourteen (57%) deaths can be attributed to
neurological death according to the definition in the methods
section.
Results of univariate analysis are shown in Table 3. On
univariate analysis, local control of the primary tumor at
time of second course and the calculated BMV after the
first course correlated significantly with OS. For multivariate
analysis we looked at the influence of ds-GPA, which already
includes various clinical parameters, and additional non-
included clinical parameters like aggregated treated tumor and
brain metastases velocity. Results are shown in Table 4. BMV
remained significantly correlating with OS [p = 0.04; HR: 1.10
(1.00–1.21)].
Toxicity
Within 197 treated lesions 14 sites of RN were observed in
10 (23.8%) patients. None of the patients suffered from severe
FIGURE 4 | Kaplan-Meier-Plot for overall survival grouped by ds-GPA ≤2 vs.
>2 after time of first diagnosis of brain metastases. Median overall survival for
ds-GPA >2 after diagnosis of first brain metastasis has not been reached. For
ds-GPA ≤2: median OS of 21 months (95% CI: 17-NA).
FIGURE 5 | Kaplan-Meier-Plot for Overall Survival grouped by BMV risk group.
For low-risk group median OS has not been reached after first DBF. Combined
intermediate /high-risk group: median OS of 10 months (95%CI: 7-NA).
symptoms. Treatment was only needed for symptomatic RN
(n = 5, 35.7%). All symptoms resolved after a short course of
dexamethasone as temporary treatment and no resection was
needed in any of our patients.
Eighteen of Forty-One (one patient did not have a FU within
90 days) patients (43.9%) developed acute toxicities, with grade
3 in 2 (4.8%), grade 2 in 11 (26.8%), and grade 1 in 6 (14.6%).
Eighteen of all Forty-Two patients suffered from low-grade late
toxicities: 2 (4.8%) with grade 3, 14 (33.3%) with grade 2, and 2
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TABLE 3 | Univariate analysis of correlation to overall survival course-specifically.
Variable P HR (95% CI)
1st course GPA 1st course (0–2 vs. 2.5–4) 0.05 0.28 (0.08–1.02)
Primary tumor controlled at 1st course 0.85 1.13 (0.31–4.08)
No. of treated metastases at 1st course 0.92 1.02 (0.65–1.61)
Aggregated tumor volume at 1st course 0.64 0.99 (0.93–1.05)
2nd course GPA 2nd course (0–2 vs. 2.5–4) 0.15 0.67 (0.39–1.16)
Primary tumor controlled at 2nd course 0.02 0.24 (0.07–0.80)
No. of treated metastases at 2nd course 0.64 1.07 (0.81–1.40)
Aggregated tumor volume at 2nd course 0.32 0.91 (0.76–1.10)
BMV at 2nd course 0.03 1.11 (1.01–1.21)
Values are numbers (percentage) except where noted otherwise.
GPA, Graded prognostic assessment score; BMV, Brain metastasis velocity.
Bold values indicate the significance level of p < 0.05.
TABLE 4 | Multivariate analysis of correlation to overall survival course-specifically.
Variable P HR (95% CI)
1st course GPA at 1st course (0–2 vs. 2.5–4) 0.10 0.62 (0.34–1.10)
Aggregated tumor volume at 1st course 0.40 0.97 (0.91–1.04)
2nd course GPA at 2nd course (0–2 vs. 2.5–4) 0.76 0.91 (0.51–1.63)
Aggregated Tumor volume at 2nd course 0.36 0.92 (0.76–1.11)
BMV at 2nd course 0.04 1.10 (1.00–1.21)
Values are numbers (percentage) except where noted otherwise.
GPA, Graded prognostic assessment score; BMV, Brain metastasis velocity.
Bold values indicate the significance level of p < 0.05.
(4.8%) with grade 1. No grade 4 or 5 toxicity occurred. Figure 6
shows distribution of observed toxicity. Considering presenting
symptoms, we observed edema as the most common acute and
chronic side effect, provided that edemawas diagnosed on regular
follow-up MRI scans. It was followed by headache and vertigo,
which were defined clinically. Detailed symptoms and grades of
acute and late toxicity are reported for patients individually in
tables in the Supplementary Material.
DISCUSSION
Administering SRS only has become the accepted standard of
care in treatment of limited number of newly diagnosed brain
metastases (2, 4, 6, 9, 12). Compared to WBRT, this approach
significantly reduces the risk for neurocognitive impairment
(3–5), while at the same time accepting higher rates of distant
brain relapse of up to 60% (4, 6, 9, 12). For the frequent scenario
of newly occurring brain metastases after initial SRS treatment,
a valid standard of care has not been established by prospective
trials. WBRT is still the predominantly used treatment option
whereas the application of repeated courses of SRS represents an
emerging concept, but still provokes safety concerns, since only
little data exists.
Recently, a retrospective analysis of 95 patients with 652
metastases treated with repeated SRS only showed that newly
diagnosed metastases could be treated safely and effectively with
FIGURE 6 | Toxicity. Acute toxicity graded according to Criteria for Adverse
Events (CTCAE v4.0) during and ≤90 days after respective course of SRS;
chronic toxicity occurring >90 days after respective course of SRS. Graph
shows highest grade of toxicity observed for individual patients during any
course of treatment.
additional courses of SRS (13). Notwithstanding the well-known
high rate of distant intracranial progression, only 20% of patients
within this study eventually receivedWBRT as salvage treatment.
The authors concluded that WBRT might even be avoided
completely for patients with brain metastases. Our findings
support this conclusion with a comparable rate of administered
WBRT in 17% of our patients.
Although all existing data is limited by the recognized biases
of retrospective analyses, patients treated with multiple courses
of SRS have acceptable rates of toxicity and no sign of increased
neurological death (12, 14, 16–18, 31). Overall, only 14 sites of
RN were observed in 197 treated lesions (7%) within our cohort,
which is reasonable and comparable to incidences reported in
previous studies (14, 16, 30, 32–34). Still, no recommendation
exists to what extent repeat radiosurgery is truly safe and what
parameters regarding dose overlap should be used to judge about
safety. It seems prudent to apply the same general constraints
as in first course SRS and to avoid significant dose overlap (e.g.,
>50% IDL overlap). Also, overall survival is very favorable in our
cohort and—although it rather reflects careful patient selection—
it is reassuring that deferring WBRT in such patients appears to
be a reasonable approach.
It remains controversial which subpopulation of BM patients
benefits most from local treatment including repeat SRS (35–
37). Determination of predictive factors and development of
prognostic indices is crucial in deriving a solid basis for decision-
making. The GPA, developed to guide these decisions, has been
validated in WBRT as well as SRS treated brain metastases
patients (19, 21). Recently, it has been expanded and validated
to a disease specific prognostic score (20, 38), even incorporating
information of tumor specific mutations (39). Interestingly, as
reported by Shultz et al. and Yamamoto et al., GPA remained
valid as a prognostic tool for repeat SRS (14, 23). Within our
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cohort the ds-GPA on univariate and multivariate analysis did
not prove to be predictive for overall survival. However, the
survival curves split significantly. Interestingly, ds-GPA did not
change significantly over time.
Various models assisting clinicians in deciding between
administration of WBRT or SRS as initial treatment have been
developed. All of them intend to enable estimation of risk of
Rodrigues et al. (40) and time to Ayala-Peacock et al. and
Press et al. (41, 42) DBF. All of these studies included the
number of primarily diagnosed metastases in their scoring
system, as it was significantly predictive for early DBF after
initial treatment. However, the effect of the estimated number
of future metastases or of the dynamics of relapse on overall
survival has so far not been investigated. Therefore, an innovative
and promising new metric BMV has been developed (24). BMV
was established by analysis of 737 patients treated with upfront
SRS only for new brain metastases and represents the rate of
new metastases that develop over time. The value can be re-
calculated over a patient’s disease course multiple times and
stays prognostic. A multi-institutional study with almost 3,000
has recently validated the BMV as a dominant predictor for OS
but the full results have not been published yet (43). BMV has
also been included into an announced web-based predictive tool
which is not online yet (44). With a median BMV of 3.5 new
metastases/year (range: 0.3–22.1) our cohort compared favorably
to the reported median BMV of 5.5 (range: 0.2–156.4) by Farris
et al. BMV correlated significantly with OS when analyzed as
a continuous variable and when factored in the suggested risk
stratified groups (BMV <4, 4–13, >13). Higher BMV predicted
for shorter OS, especially when low and high-risk groups were
directly compared [P = 0.0006, HR (95%CI) = 23.78 (3.88–
145.74)] and BMV remained the only significant factor for OS
in the multivariable model. Our findings with a median OS of
10 months for the combined intermediate and high-risk group
exceed values previously reported by the authors (8.2 and 4.3
months), which might be a combined effect of small sample size
and favorable patient selection. BMV seems to be a powerful
and promising prognostic metric, even in a small cohort such as
ours.
The results of the present study are prone to bias inherent
to retrospective studies, particularly selection bias. Furthermore,
the ability to analyze patient-specific variables with regard to
predictive character is limited due to the small cohort of 42
patients and statistics beyond univariate analysis should be
viewed with caution.
CONCLUSION
Considering the excellent local control rate, the low toxicity
profile and the long OS observed within this study, distant
intracranial relapse should not preclude administering SRS: In
selected patients with various relapses of brain metastases (DBF)
amenable to SRS, repeat courses of SRS can safely be administered
to defer or even avoid WBRT. The innovative metric BMV also
proved to be prognostic in our cohort and should be further
evaluated as a decision-guiding metric.
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